Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017, 36(36):5098-5109. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NYXXSGM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TnTWlEPTB;MD6wNFAxPTF|IN88US=> M{HxRXNCVkeHUh?=
NCI-H1703 NWnFT3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW3TWM2OD1yLkCwNFkxOiEQvF2= NUT2UXA{W0GQR1XS
KASUMI-1 NYTvXpNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMEC2PFIh|ryP NXO3dGlQW0GQR1XS
CGTH-W-1 NVrOXGtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\2TWM2OD1yLkCwO|IzKM7:TR?= MnfoV2FPT0WU
A204 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqzWHhKSzVyPUCuNFA6QTJizszN MnHmV2FPT0WU
HOP-62 NIfaOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\aTWM2OD1yLkGwPFM3KM7:TR?= M361PHNCVkeHUh?=
H-EMC-SS M3jkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfJd49KSzVyPUCuNVExODVizszN MYXTRW5ITVJ?
KU812 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu5fnhWUUN3ME2wMlE3PTd5IN88US=> NX7pcXhQW0GQR1XS
EM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMU[4NVYh|ryP NYTTNIt3W0GQR1XS
LAMA-84 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLpOmhKSzVyPUCuNVc3PjVizszN NUD5OYhHW0GQR1XS
JAR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jzOWlEPTB;MD6yN|k5QSEQvF2= MUPTRW5ITVJ?
G-361 NEnMO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwM{KzNlUh|ryP M1Xl[3NCVkeHUh?=
KG-1 NWHHV49DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDNT5BKSzVyPUCuN|c3PDJizszN NWrwdoo5W0GQR1XS
BV-173 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwM{mzNkDPxE1? MXvTRW5ITVJ?
K5 M{W4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNEKxNlch|ryP M3uwbHNCVkeHUh?=
MEG-01 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ZTWM2OD1yLkSyN|YyKM7:TR?= NX7hOmhHW0GQR1XS
MFM-223 M{DYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu0WZFKSzVyPUCuOFQ4PzZizszN NEW0OlJUSU6JRWK=
BE-13 NUWwdJE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTaTWM2OD1yLkWxNFA5KM7:TR?= NFjT[nJUSU6JRWK=
NEC8 NXnv[2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7W[VRPUUN3ME2wMlczOTF|IN88US=> NX[xVJNlW0GQR1XS
SW756 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTGTWM2OD1yLkm5PFQ3KM7:TR?= Mlr0V2FPT0WU
A2780 NVzXWZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S0N2lEPTB;MT6wNVE1PiEQvF2= NYrCSYxWW0GQR1XS
NB14 M2nJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPpW4FKSzVyPUGuNFE5ODFizszN MkPxV2FPT0WU
H4 M3fOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwME[0NlIh|ryP MnPPV2FPT0WU
SK-OV-3 NYmy[5piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6wNFNoUUN3ME2xMlA3PjN|IN88US=> MWXTRW5ITVJ?
AN3-CA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3SG1KSzVyPUGuNFg{QDlizszN MVvTRW5ITVJ?
A427 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L3dGlEPTB;MT6xNFM5OSEQvF2= NVrXWmQ3W0GQR1XS
ES7 M3Hkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1zLkGxN|M1KM7:TR?= M4[4bnNCVkeHUh?=
AGS NF3oVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rKV2lEPTB;MT6xNVM6PSEQvF2= MVzTRW5ITVJ?
G-402 NGrMVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTmTWM2OD1zLkG0Olk1KM7:TR?= NGXldFFUSU6JRWK=
ES5 M2DCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwMUeyOFgh|ryP M{frdnNCVkeHUh?=
DEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvVTWM2OD1zLkK1OFU4KM7:TR?= NV7XTYRpW0GQR1XS
NB10 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD1zLkOyOVU4KM7:TR?= MX3TRW5ITVJ?
NCI-H1581 NIPKVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITGZlZKSzVyPUGuN|kxPDJizszN MlzvV2FPT0WU
D-566MG NGPVVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPsWlNKSzVyPUGuOFA3QDNizszN M{G5T3NCVkeHUh?=
LXF-289 NEWzfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XNTGlEPTB;MT60N|k6PiEQvF2= MWfTRW5ITVJ?
BT-549 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi5XlJKSzVyPUGuOVY6ODlizszN M2LXfHNCVkeHUh?=
NKM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwNkC1OVYh|ryP M{\RTHNCVkeHUh?=
SW780 NWHYZ|hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXHTWM2OD1zLk[1NVU5KM7:TR?= M1P2Z3NCVkeHUh?=
NCI-H292 NUj3WW9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfDTWM2OD1zLk[2N|g{KM7:TR?= MV;TRW5ITVJ?
HMV-II NGTibIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTETWM2OD1zLkewOFg5KM7:TR?= MkLtV2FPT0WU
ALL-PO MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwOECwNVUh|ryP Ml7OV2FPT0WU
UACC-257 M{jOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwOEKxOlMh|ryP NELEdmFUSU6JRWK=
PA-1 NEDMfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3sZWRKSzVyPUGuPFI4OjVizszN MkG2V2FPT0WU
HD-MY-Z NXjrZ4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwOE[yPFEh|ryP MXrTRW5ITVJ?
HSC-4 NVPh[HlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwOUO4N|kh|ryP NGP1cmVUSU6JRWK=
GCT NV7HWINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnrTWM2OD1{LkCwPVE3KM7:TR?= Mli4V2FPT0WU
RT-112 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJwMUO0NlQh|ryP Mk\jV2FPT0WU
A172 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwMUO2NFYh|ryP M2\YNHNCVkeHUh?=
HCE-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KxT2lEPTB;Mj6yNFU6QCEQvF2= M1K0SHNCVkeHUh?=
YH-13 NIK0bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33URWlEPTB;Mj6yNVY4OSEQvF2= M3;a[HNCVkeHUh?=
DK-MG MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LwXmlEPTB;Mj6yN|g{PCEQvF2= M2r3WnNCVkeHUh?=
ACN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe4WGdrUUN3ME2yMlI{QDd3IN88US=> MXLTRW5ITVJ?
VA-ES-BJ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj3SG5KSzVyPUKuNlQ6PTdizszN NUDwRZpVW0GQR1XS
L-363 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZWIRwUUN3ME2yMlI5ODZzIN88US=> NHPQTlBUSU6JRWK=
HuH-7 NYrvdmt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjSSXZKSzVyPUKuOFIyPjVizszN NHe3ZohUSU6JRWK=
A4-Fuk MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\uWolKSzVyPUKuOFcyPjhizszN NFTuV4xUSU6JRWK=
T-24 M4j3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3OYRnUUN3ME2yMlQ5ODN5IN88US=> MXfTRW5ITVJ?
GOTO NY\uNoczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniyTWM2OD1{LkWzNFE{KM7:TR?= MlnHV2FPT0WU
MV-4-11 NXXLPHlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rmNGlEPTB;Mj61PVE3QSEQvF2= NXPYXXVKW0GQR1XS
DMS-114 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:wTnVGUUN3ME2yMlY3OzR3IN88US=> NHP6[3FUSU6JRWK=
MHH-NB-11 NGOybmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn5NJhyUUN3ME2yMlcxOjl7IN88US=> NXvQRnNzW0GQR1XS
CHP-212 NHj5fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLDTWM2OD1{LkiyNFkyKM7:TR?= NEjzNXRUSU6JRWK=
DMS-273 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe5PJRnUUN3ME2yMlkxOjB5IN88US=> Mk\GV2FPT0WU
SF295 NYHQSoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL3PIpKSzVyPUOuNFI2QTdizszN MnvZV2FPT0WU
NCI-H1563 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y3SGlEPTB;Mz6xOVAxPSEQvF2= NFv2[2ZUSU6JRWK=
NCI-H446 M4Hsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fmSGlEPTB;Mz6yNlgxPSEQvF2= M1fRS3NCVkeHUh?=
HCC1806 NXOxfmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qwZ2lEPTB;Mz6yO|Y2PyEQvF2= NF7ldHNUSU6JRWK=
SF126 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rKWWlEPTB;Mz6zNFAyPyEQvF2= MUfTRW5ITVJ?
SW982 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwM{O4O|Uh|ryP MnnWV2FPT0WU
ES8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwM{S5PVkh|ryP MXTTRW5ITVJ?
SCC-4 NYPzZ5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaNplKSzVyPUOuOVA{QTZizszN M1rEfnNCVkeHUh?=
RPMI-8226 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjjPINrUUN3ME2zMlYzPjF4IN88US=> MWXTRW5ITVJ?
EW-11 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwNkOwNlIh|ryP MWnTRW5ITVJ?
COR-L105 M33Re2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\V[mV2UUN3ME2zMlY{OzN2IN88US=> MUTTRW5ITVJ?
ES1 NV7xWI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnqTWM2OD1|LkizNFk1KM7:TR?= NVntVIhlW0GQR1XS
KMOE-2 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG1To9KSzVyPUOuPVE5ODhizszN M2LD[3NCVkeHUh?=
ABC-1 NGTZXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSdGlEPTB;Mz65N|kyOSEQvF2= NG\LNZZUSU6JRWK=
NCI-H526 M3[0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[2RopKSzVyPUOuPVkyOjZizszN MlnQV2FPT0WU
HCC1395 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwOUm0PFQh|ryP Mn3BV2FPT0WU
DU-145 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLyVW9VUUN3ME20MlEzQDJ3IN88US=> NYTmS4o3W0GQR1XS
JEG-3 NHfoZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLtOYlwUUN3ME20MlE2QTF4IN88US=> MWPTRW5ITVJ?
HCC1187 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi5SoRKUUN3ME20MlIyPTl5IN88US=> NVzvPIFqW0GQR1XS
LC-2-ad NHXtZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXlTWM2OD12LkKyNVc4KM7:TR?= NVOyTpl[W0GQR1XS
ONS-76 NIjPd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnHbnFKSzVyPUSuNlQyQTJizszN MX;TRW5ITVJ?
CAL-27 NV7qXXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTRwMkSzOFQh|ryP NXPqfotQW0GQR1XS
8-MG-BA NGTZSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwMk[2OVgh|ryP NGnwT4FUSU6JRWK=
HGC-27 NGDBfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XhO2lEPTB;ND6yPVY3KM7:TR?= MUjTRW5ITVJ?
Hs-578-T MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTRwM{G0Olgh|ryP M2DkOnNCVkeHUh?=
EW-1 M3vvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3RN2JtUUN3ME20MlU{ODF2IN88US=> MnHYV2FPT0WU
SW1573 NVnnSWlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvYTpBKSzVyPUSuOVUyPjNizszN NIjZWXVUSU6JRWK=
SNU-423 NYLXdJJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n4VmlEPTB;ND62NFc6KM7:TR?= MVzTRW5ITVJ?
HOS NEDaTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe2WGRjUUN3ME20MlY6PzdizszN NHP2NpFUSU6JRWK=
LB1047-RCC MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrkTYhKSzVyPUSuPFE1OThizszN NEnYeFlUSU6JRWK=
ChaGo-K-1 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwOEmwOFgh|ryP NY\SNGNPW0GQR1XS
A3-KAW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPKW21JUUN3ME20Mlk4OzV{IN88US=> NIX4W|ZUSU6JRWK=
CAS-1 NITKbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCfIVyUUN3ME20Mlk6QTB6IN88US=> M{DtPXNCVkeHUh?=
NBsusSR NFK2PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHEbnZKSzVyPUWuNFM2OTRizszN NYHueZdYW0GQR1XS
KM12 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTVwMkm4Nlch|ryP M2PSeHNCVkeHUh?=
NCI-H1155 NUHCcFN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXtfHdKSzVyPUWuN|gyQDVizszN NUCye5VMW0GQR1XS
EFM-19 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W4UmlEPTB;NT60NVc{PyEQvF2= MknZV2FPT0WU
D-392MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLMbJNKSzVyPUWuOVc5PDlizszN MnfhV2FPT0WU
JVM-3 NV3FXIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn2TWM2OD13LkeyN|I2KM7:TR?= NEOwTHpUSU6JRWK=
EW-16 NY\jPHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jZemlEPTB;NT63OVU5OyEQvF2= MUPTRW5ITVJ?
KARPAS-45 NEXx[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGryXpJKSzVyPUWuPFQ{OjVizszN MnLrV2FPT0WU
NCI-H28 M3ThU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTVwOEe5NVgh|ryP M2C2XnNCVkeHUh?=
COLO-829 M2TVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTVwOUG1NFQh|ryP NVrWdWo{W0GQR1XS
KM-H2 NGPpZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTEdpFKSzVyPUWuPVI{QTVizszN NULi[mNiW0GQR1XS
NCI-H82 NXm2SZZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofpTWM2OD13LkmyO|cyKM7:TR?= M33ZXnNCVkeHUh?=
OAW-42 NWfqbVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f1[mlEPTB;NT65PFgzOSEQvF2= NFTVc|hUSU6JRWK=
A704 NWG5fY1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q3[GlEPTB;Nj6xNFU4PCEQvF2= MnrTV2FPT0WU
NCI-H1048 NGLSPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT0XFZ3UUN3ME22MlExPTl7IN88US=> MXrTRW5ITVJ?
LOXIMVI M4\kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\5OpBtUUN3ME22MlEyOjR6IN88US=> NVzh[IY1W0GQR1XS
MKN45 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCyTWM2OD14LkK2NFE3KM7:TR?= MXTTRW5ITVJ?
D-502MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXPTWM2OD14LkK4PFU4KM7:TR?= Mnz2V2FPT0WU
HUTU-80 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GyWGlEPTB;Nj60NVY5QCEQvF2= NEW4XY1USU6JRWK=
S-117 NFjzO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZwNUCyOlch|ryP MnnhV2FPT0WU
HCC1569 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTZwNUO3N|ch|ryP NYT0eoRjW0GQR1XS
J-RT3-T3-5 M3j1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDyTZJKSzVyPU[uOVQ2PzJizszN NYjBfYJjW0GQR1XS
OC-314 NGW1bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPKTWM2OD14LkmxNVU6KM7:TR?= MV\TRW5ITVJ?
SNU-449 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjWUmRoUUN3ME23MlAyODd{IN88US=> NVSwdZQ5W0GQR1XS
NCI-H720 NV;mVm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdwMUmzOFUh|ryP MV;TRW5ITVJ?
KP-N-YS NIDVdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iyfGlEPTB;Nz6yNFczKM7:TR?= MVrTRW5ITVJ?
IGROV-1 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfndlhkUUN3ME23MlMzOzh4IN88US=> MVTTRW5ITVJ?
SK-PN-DW Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jpXWlEPTB;Nz60PFE2KM7:TR?= NEXrOXlUSU6JRWK=
HCC1419 NYPaRZZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPLTllVUUN3ME23MlU{KM7:TR?= NYLvfGRvW0GQR1XS
HAL-01 NH7j[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELYRmRKSzVyPUeuOlA3PDRizszN M{\UUnNCVkeHUh?=
HCC2998 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;qWXY4UUN3ME23MlYxPzR|IN88US=> MUnTRW5ITVJ?
SK-N-FI M4rMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTmTWM2OD15Lk[zNFM{KM7:TR?= NGf5dIdUSU6JRWK=
GI-ME-N NYrHfll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLIe2RvUUN3ME23MlY1QTN2IN88US=> M2DLc3NCVkeHUh?=
SW1088 M2HURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTdwNkW4NlYh|ryP M1z3PHNCVkeHUh?=
IA-LM NFjsfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITWRlZKSzVyPUeuOlg3OTNizszN MVnTRW5ITVJ?
SK-NEP-1 NGfaWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;OZWlEPTB;Nz62PVYyKM7:TR?= MUjTRW5ITVJ?
MDA-MB-415 NIXne4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzqTWM2OD15Lki5NVg3KM7:TR?= MVvTRW5ITVJ?
COLO-800 NYOx[VJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[4TWM2OD15Lkm0OFkzKM7:TR?= NWTVW4tUW0GQR1XS
NCI-H2228 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS4XW1KSzVyPUiuNVU4QDNizszN NFPubW5USU6JRWK=
D-423MG NH7iPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HUU2lEPTB;OD6yNVczKM7:TR?= M4D5cXNCVkeHUh?=
TE-1 NILVUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRThwNESzNVYh|ryP NGq4WnZUSU6JRWK=
NOS-1 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPFTWM2OD16LkWxOVM1KM7:TR?= MUnTRW5ITVJ?
8505C MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrCTWM2OD16Lk[0PFI1KM7:TR?= MXvTRW5ITVJ?
HEC-1 NYXVNFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRThwN{i0N|kh|ryP MmHzV2FPT0WU
TE-11 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXycmtzUUN3ME24Mlk6PTVzIN88US=> MkLiV2FPT0WU
CTB-1 M4rvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTlwMEG0N|Mh|ryP NU\kfZRkW0GQR1XS
TGBC11TKB Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;FWGx1UUN3ME25MlAzOjRzIN88US=> MXfTRW5ITVJ?
NB17 M3nN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ON2JKSzVyPUmuNVg5PyEQvF2= NWrqe4FMW0GQR1XS
Becker MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GxOWlEPTB;OT60NVk1PCEQvF2= MoTCV2FPT0WU
SN12C Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvB[YNFUUN3ME25MlQ2OjN2IN88US=> MUfTRW5ITVJ?
COLO-320-HSR M{\pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fEfmlEPTB;OT62NFI{PyEQvF2= MV7TRW5ITVJ?
D-283MED NEj5SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnoeHRKSzVyPUmuOlMxPzJizszN MWLTRW5ITVJ?
D-263MG NVrCUINnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTqdmVOUUN3ME25Mlg{Ozh2IN88US=> M3rQbnNCVkeHUh?=
MEL-JUSO NGXIUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTlwOUCxNlch|ryP M1\K[HNCVkeHUh?=
T98G NX;DNnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnnboZxUUN3ME25MlkxOjB|IN88US=> NEK5SItUSU6JRWK=
HLE MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTlwOUC5NFkh|ryP M4nZOnNCVkeHUh?=
Ca9-22 NIHNcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LOVWlEPTB;MUCuNFY3PSEQvF2= MknuV2FPT0WU
OS-RC-2 M4TZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvYTWM2OD1zMD6xNFQ2KM7:TR?= NHSwVoVUSU6JRWK=
T47D NVjnNI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xr[GlEPTB;MUCuNVU2KM7:TR?= M4LIenNCVkeHUh?=
GI-1 NVn3W5pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\xUmlqUUN3ME2xNE4{PTN|IN88US=> MljlV2FPT0WU
NUGC-3 NEPCeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGzXWJrUUN3ME2xNE41PDB{IN88US=> NWDtOZM1W0GQR1XS
MDA-MB-361 NIrPR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M165WGlEPTB;MUCuOFQ{OiEQvF2= MWnTRW5ITVJ?
SCC-15 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm0W2xnUUN3ME2xNE41PzF6IN88US=> M3\wVXNCVkeHUh?=
KS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r0S2lEPTB;MUCuOlMxOSEQvF2= M3rkbXNCVkeHUh?=
CAL-12T M17tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHVTWM2OD1zMD62N|YyKM7:TR?= NWDLd5V2W0GQR1XS
OVCAR-4 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFyLkewOlgh|ryP MmX0V2FPT0WU
HuP-T4 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonCTWM2OD1zMT6wN|I5KM7:TR?= NYe1ZXZXW0GQR1XS
NCI-H358 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjpfnNyUUN3ME2xNU4zPjV5IN88US=> Mlr3V2FPT0WU
HO-1-N-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvTpZOUUN3ME2xNU4{Ozl6IN88US=> NWPV[VBlW0GQR1XS
NH-12 NEHaVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HZfWlEPTB;MUGuOVM4QCEQvF2= MX7TRW5ITVJ?
MOLT-4 NUXjWXNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFzLkW5PFUh|ryP NGDOSYJUSU6JRWK=
K-562 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLYWnBSUUN3ME2xNU44OjR6IN88US=> NXfySmU2W0GQR1XS
ES6 NUPSNYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFzLki1PFEh|ryP NYKxZ3VEW0GQR1XS
RO82-W-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SxTGlEPTB;MUGuPVA3PCEQvF2= NYHqZ2hNW0GQR1XS
Ramos-2G6-4C10 M3\tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFzLkmzNkDPxE1? MknIV2FPT0WU
23132-87 NFy0fldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXyWFhnUUN3ME2xNk4xQDJzIN88US=> M2XHVnNCVkeHUh?=
A549 M2HxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTUe4FKUUN3ME2xNk4{Ojh3IN88US=> MXzTRW5ITVJ?
NCI-H23 NED0SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoftTWM2OD1zMj61NFI3KM7:TR?= M2nuT3NCVkeHUh?=
H9 NHHOdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH5TWM2OD1zMj61OVc4KM7:TR?= NV3TbIcyW0GQR1XS
LB771-HNC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P3RmlEPTB;MUKuO|Y2KM7:TR?= NWrsRnl7W0GQR1XS
QIMR-WIL NEj2OGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDkTWM2OD1zMj64NlU5KM7:TR?= MVTTRW5ITVJ?
HSC-3 NGjW[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF{LkmyO|Yh|ryP NYPrcGVtW0GQR1XS
PFSK-1 M4H4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHX[ZlRUUN3ME2xNk46PTB5IN88US=> MVPTRW5ITVJ?
ETK-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q5ZmlEPTB;MUOuNFc4QSEQvF2= MVrTRW5ITVJ?
SW1710 NUfPTYtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrrTWM2OD1zMz6zOlQyKM7:TR?= M4rQUHNCVkeHUh?=
COLO-684 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjYTWM2OD1zMz60OVQyKM7:TR?= NYXXOnE4W0GQR1XS
RPMI-7951 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzkTWM2OD1zMz61NVM3KM7:TR?= NFn2fGlUSU6JRWK=
A101D NVnUWnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfic|BKSzVyPUGzMlU{PDlizszN NVvYfYlzW0GQR1XS
KE-37 NGPDe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF|LkW4PFch|ryP NHjMXGRUSU6JRWK=
SiHa M1fzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF|LkizOFYh|ryP M1;kdnNCVkeHUh?=
NCI-H226 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXiWWVKSzVyPUGzMlg5ODhizszN M2L3W3NCVkeHUh?=
DB MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqwe4p2UUN3ME2xN{46QTJ6IN88US=> NYL2emdkW0GQR1XS
HT-1197 NI\IXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXFNJJKSzVyPUG0MlA5ODlizszN MVPTRW5ITVJ?
SBC-5 M4T4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG5bmo4UUN3ME2xOE4yOzZ{IN88US=> M2W3VXNCVkeHUh?=
VMRC-RCZ M33E[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDn[2NKSzVyPUG0MlU4PzRizszN MUnTRW5ITVJ?
697 NHTJ[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rIT2lEPTB;MUSuOlI4KM7:TR?= M13hVXNCVkeHUh?=
OMC-1 NFLZV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jqcGlEPTB;MUSuO|g5QCEQvF2= NHf1V3BUSU6JRWK=
SKG-IIIa MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XzbWlEPTB;MUSuPFAxOSEQvF2= MU\TRW5ITVJ?
DOK M1naeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O4RWlEPTB;MUSuPVk{OyEQvF2= NULFSYpMW0GQR1XS
NCI-H2029 M3\JXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nHdmlEPTB;MUWuN|YxOiEQvF2= Mme1V2FPT0WU
NCI-H2009 NWr1b3JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfDdWVNUUN3ME2xOU42ODl3IN88US=> NW\oR|RMW0GQR1XS
LK-2 NGn2eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5TWM2OD1zNT62OFQ6KM7:TR?= MWfTRW5ITVJ?
NCI-H661 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fXXWlEPTB;MUWuPVA4PSEQvF2= MWrTRW5ITVJ?
GT3TKB NXv3Vo9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n1TWlEPTB;MU[uNFY4PiEQvF2= NFLFbVFUSU6JRWK=
GP5d M{ftfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4LkO0NkDPxE1? MoSyV2FPT0WU
SK-MEL-2 M1PsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XsdGlEPTB;MU[uOFQ5PSEQvF2= NUC3SIZOW0GQR1XS
SK-UT-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL6OFQxUUN3ME2xOk42PjVizszN MXzTRW5ITVJ?
NB7 NVmwUXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF4Lk[5O|Eh|ryP NEnKRZRUSU6JRWK=
NCI-H460 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon3TWM2OD1zNj63N|I3KM7:TR?= NY\S[JRiW0GQR1XS
8305C NYXVN3NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF4Lke4O|ch|ryP M3X4VXNCVkeHUh?=
CaR-1 NUHJN3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX4UIRYUUN3ME2xOk45OTFzIN88US=> MVvTRW5ITVJ?
D-247MG M2XCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\5fmlEPTB;MU[uPFYzPSEQvF2= MmTaV2FPT0WU
LoVo MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF4Lkm0PFgh|ryP NHThTpNUSU6JRWK=
NCI-H2405 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LBTGlEPTB;MUeuNVkxQCEQvF2= M3L3T3NCVkeHUh?=
AU565 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2noVWlEPTB;MUeuNlI2KM7:TR?= MlLqV2FPT0WU
OCI-AML2 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLXXodKSzVyPUG3MlU{OTdizszN NXHIbItMW0GQR1XS
22RV1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HXe2lEPTB;MUeuOVg5PCEQvF2= Mn3ZV2FPT0WU
HT-144 NUe4OHhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFbINzUUN3ME2xO{43PTl6IN88US=> MUjTRW5ITVJ?
HuO9 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;jR2lEPTB;MUeuO|A{OSEQvF2= M1fuWnNCVkeHUh?=
Daoy M4PLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\MTWM2OD1zNz63NVg1KM7:TR?= MWHTRW5ITVJ?
SJRH30 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn2bnFKSzVyPUG3Mlg1QDlizszN NXL6fGRYW0GQR1XS
CHL-1 M2jMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjGS29TUUN3ME2xO{46OjR7IN88US=> NYHj[WcyW0GQR1XS
J82 M1XOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq4TWM2OD1zNz65OlM2KM7:TR?= NXW4d2ZzW0GQR1XS
COR-L23 M3PW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS3UXZEUUN3ME2xPE4xODFzIN88US=> MVnTRW5ITVJ?
SNU-C2B NHXOSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXjTWM2OD1zOD6yNlc3KM7:TR?= NV;QXFh7W0GQR1XS
NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4SYVSUUN3ME2xPE41PjF3IN88US=> M3rGbHNCVkeHUh?=
MHH-PREB-1 M{PCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXWUJFKSzVyPUG4MlU3QTdizszN M3joW3NCVkeHUh?=
ES3 NHq1O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF6LkW4PFMh|ryP M1fxTnNCVkeHUh?=
MDA-MB-231 NF7Lc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6Lk[1NFIh|ryP MXfTRW5ITVJ?
MN-60 M{fvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF7LkC1PVIh|ryP NEiyO2pUSU6JRWK=
EPLC-272H MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF7LkO3NFgh|ryP MWnTRW5ITVJ?
SW948 NIfQNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fzPWlEPTB;MUmuN|k{PCEQvF2= NXvJV|VsW0GQR1XS
MOLT-13 NVnXWJN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XoVWlEPTB;MUmuOFU1PiEQvF2= MWXTRW5ITVJ?
HL-60 M2j5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTmd5NzUUN3ME2yNE4zOTRzIN88US=> MXfTRW5ITVJ?
CP50-MEL-B MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;jcmlEPTB;MkCuOFc1QCEQvF2= NXTjTo5JW0GQR1XS
NTERA-S-cl-D1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7SO4RKSzVyPUKwMlQ6PzhizszN MmDVV2FPT0WU
KINGS-1 M2Tqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJyLke5Olch|ryP NEXDRoRUSU6JRWK=
DOHH-2 NYnZT4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJyLkmwOkDPxE1? Mn3DV2FPT0WU
BB65-RCC NXfZXHRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTnZ3pKSzVyPUKwMlkzQDVizszN M4W3bHNCVkeHUh?=
NB12 NIT0cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u0WGlEPTB;MkGuNFM6PCEQvF2= NHL4OJpUSU6JRWK=
KY821 NYDyfY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W5SWlEPTB;MkGuOVgzKM7:TR?= Ml6zV2FPT0WU
PSN1 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfhSGdKSzVyPUKxMlY1PTNizszN M{TOUHNCVkeHUh?=
EGI-1 NEf5SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\4[XNKSzVyPUKxMlc1PTRizszN MlTOV2FPT0WU
CTV-1 NEPZbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;nTWM2OD1{Mj6zNFMyKM7:TR?= NWXYXoZ7W0GQR1XS
TI-73 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXryNJYzUUN3ME2yNk4{PDl6IN88US=> NGS4fY9USU6JRWK=
LCLC-103H M3jSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4npeGlEPTB;MkKuOFc2OiEQvF2= M33rdHNCVkeHUh?=
D-542MG NF7nN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm4RoZtUUN3ME2yNk42PTV6IN88US=> MWXTRW5ITVJ?
ATN-1 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXUTWM2OD1{Mj62OFM6KM7:TR?= M2GzenNCVkeHUh?=
SK-MEL-1 NGXBN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ{LkizOlgh|ryP NXPzbJJ[W0GQR1XS
HDLM-2 NI\LZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK2SWtKSzVyPUKzMlE1PzhizszN M13nbXNCVkeHUh?=
UM-UC-3 NITTOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ|LkG5OFQh|ryP NXLqXY1uW0GQR1XS
NCI-H1573 NUSyR3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjTWXZKSzVyPUKzMlQ3QDFizszN NHL3O|NUSU6JRWK=
NCI-H520 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XoXmlEPTB;MkOuOFk1QCEQvF2= MWPTRW5ITVJ?
ESS-1 NVPSfolQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37SWGlEPTB;MkOuPFA2QSEQvF2= NYnoc5dxW0GQR1XS
COR-L88 NUnPVWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\3TWM2OD1{Mz65OFc2KM7:TR?= MYDTRW5ITVJ?
TGBC24TKB NWLJeI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnhTWM2OD1{ND6wN|EzKM7:TR?= MYXTRW5ITVJ?
HCC1937 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHKTWM2OD1{ND6xJO69VQ>? NUP4VldFW0GQR1XS
RS4-11 NFvVelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\FOItKSzVyPUK0MlE1OiEQvF2= NXHFdGNCW0GQR1XS
HCC38 NHXJdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ2LkKzPVQh|ryP NUjNXWdwW0GQR1XS
RPMI-2650 NIXScXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L3O2lEPTB;MkSuOlE3OiEQvF2= NVzQXXpwW0GQR1XS
P12-ICHIKAWA NGDFfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qyO2lEPTB;MkSuOlI2QCEQvF2= M3LPNHNCVkeHUh?=
YAPC NXe3OIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nFTGlEPTB;MkSuPFIyPCEQvF2= MoTZV2FPT0WU
NB13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonHTWM2OD1{NT6yOlEyKM7:TR?= NXfo[FB1W0GQR1XS
SK-N-AS NWfidmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHQTWM2OD1{NT64OVg1KM7:TR?= Ml23V2FPT0WU
SK-N-DZ MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW4V49kUUN3ME2yOk4xPDlizszN MXPTRW5ITVJ?
LS-411N Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;l[HdKSzVyPUK2MlIxOzhizszN NVny[G5RW0GQR1XS
NCI-H810 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ4LkOxNVIh|ryP NFvUSXhUSU6JRWK=
NCI-SNU-1 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP1[4NKSzVyPUK2MlU1PTRizszN NIHzN2pUSU6JRWK=
HH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonUTWM2OD1{Nj61OVI6KM7:TR?= MXfTRW5ITVJ?
U-2-OS NX\4PVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPOSY1KSzVyPUK2Mlc{QDJizszN NXWzW2h4W0GQR1XS
SF539 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXsTWM2OD1{Nj64NFE5KM7:TR?= NVLqco5iW0GQR1XS
NCI-H2052 NX6ybotiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7FRZFnUUN3ME2yO{4xQDZizszN NV7sV2dSW0GQR1XS
A673 NUXxdI96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG4TWM2OD1{Nz6yNVAzKM7:TR?= NHy5VmhUSU6JRWK=
WM-115 NELhPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zDTWlEPTB;MkeuO|c3PyEQvF2= NF3Xd5NUSU6JRWK=
SW48 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfiTWM2OD1{Nz64NFA2KM7:TR?= NGrkbGNUSU6JRWK=
NOMO-1 M{nSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL6ZWs{UUN3ME2yO{45PTN{IN88US=> Mk\vV2FPT0WU
PC-3 M3XT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDTTWM2OD1{Nz64PVQyKM7:TR?= M4rjd3NCVkeHUh?=
UMC-11 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJ5LkmzOFMh|ryP M2K1XnNCVkeHUh?=
U-118-MG MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PpTmlEPTB;MkiuNFEzOyEQvF2= MkPYV2FPT0WU
NCI-H2452 NVHZd3BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\QTGlEPTB;MkiuNFgzOiEQvF2= NWDLfGJIW0GQR1XS
CAMA-1 NFLLU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3SUIRKSzVyPUK4Mlg2PjRizszN NVT0ZWxjW0GQR1XS
MC-IXC MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLfmlEPTB;MkmuNlM3PiEQvF2= MWHTRW5ITVJ?
ES4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\YS2lEPTB;MkmuN|E4OiEQvF2= M3qxVHNCVkeHUh?=
BHT-101 NGjlW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjqNFR{UUN3ME2yPU4{OjFizszN Ml7kV2FPT0WU
KP-4 NULEdFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlriTWM2OD1{OT61NVYh|ryP NIrCZYJUSU6JRWK=
CAL-54 NV63[HFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;GdWRKSzVyPUK5MlU1PDVizszN MUHTRW5ITVJ?
5637 NEHq[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m1dmlEPTB;MkmuOlQzOSEQvF2= NV34VHd6W0GQR1XS
MOLT-16 M3fL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLOolYUUN3ME2yPU44OjZ7IN88US=> NUTJOYE5W0GQR1XS
Ca-Ski MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInPPWZKSzVyPUK5Mlk1PiEQvF2= Mn3tV2FPT0WU
AsPC-1 NUTPS5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TPcWlEPTB;M{CuNFIyOiEQvF2= NIXa[FlUSU6JRWK=
MSTO-211H NIr1dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCybmJKSzVyPUOwMlE2KM7:TR?= MUPTRW5ITVJ?
L-428 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrYTWM2OD1|MD60NFUh|ryP MnTmV2FPT0WU
SW1463 NIGyPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP5UY1KSzVyPUOwMlU{QDNizszN MXrTRW5ITVJ?
NCI-H1648 NXnib2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHCeXpKSzVyPUOwMlU2PzRizszN MVXTRW5ITVJ?
CAKI-1 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf1TWM2OD1|MD63O|AzKM7:TR?= M4TRXHNCVkeHUh?=
YKG-1 NFj5dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNzLkCyOlMh|ryP Mn7aV2FPT0WU
A2058 NILj[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNzLkGxOlQh|ryP MoLmV2FPT0WU
A375 M{Pi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\5dGlEPTB;M{GuNVY6PiEQvF2= M4riTHNCVkeHUh?=
SNB75 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu1XnUyUUN3ME2zNU4zPDN3IN88US=> NXrr[mlQW0GQR1XS
SK-HEP-1 M1vGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PXe2lEPTB;M{GuOFI4OSEQvF2= NVn5OIFkW0GQR1XS
ME-180 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j4eWlEPTB;M{GuOlU1OiEQvF2= MojpV2FPT0WU
NCI-H209 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvnSXZKSzVyPUOxMlgzPDdizszN NHzYU2ZUSU6JRWK=
HC-1 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO3TWM2OD1|Mj6xOFQ3KM7:TR?= MY\TRW5ITVJ?
LB373-MEL-D M{f6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTN{LkG5O|Eh|ryP NGDTWnpUSU6JRWK=
SNU-387 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fme2lEPTB;M{KuN|E6OSEQvF2= NUfZcFZ7W0GQR1XS
C32 M1Xx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN{LkOzOVMh|ryP MX\TRW5ITVJ?
EW-13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN{Lkm0NFgh|ryP MUHTRW5ITVJ?
BFTC-905 M{fDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LnNGlEPTB;M{OuOVE{PiEQvF2= NEfxNHJUSU6JRWK=
NCI-H1299 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHhRplKSzVyPUOzMlU3OjFizszN NHvyUZpUSU6JRWK=
LU-135 M4nrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXhTWM2OD1|Mz64NFEh|ryP NXfuc5VPW0GQR1XS
NCI-H2122 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTN|Lkm5OlYh|ryP NGfabZBUSU6JRWK=
SK-LMS-1 NUjmOHZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPv[mlKSzVyPUO0MlQyODdizszN MkTpV2FPT0WU
LNCaP-Clone-FGC NYnFbos3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLCTWM2OD1|ND64OVE2KM7:TR?= MUfTRW5ITVJ?
NCI-H1092 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzKcIJKSzVyPUO1MlI4PDdizszN MVHTRW5ITVJ?
MS-1 M{n4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN3LkOwN|gh|ryP NUXFXWEzW0GQR1XS
KYSE-510 NEHsOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xTWM2OD1|NT61NFQzKM7:TR?= MlmxV2FPT0WU
NCI-H1793 M2HhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\jWmlEPTB;M{WuOlU1PSEQvF2= MnGyV2FPT0WU
MIA-PaCa-2 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX0eHBKSzVyPUO2MlA1QTZizszN MVHTRW5ITVJ?
EW-22 NWfDNG54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN4LkSwO|Ih|ryP NEDt[4tUSU6JRWK=
IGR-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILrR2JKSzVyPUO2MlgyQDRizszN MUfTRW5ITVJ?
HT-1080 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;pTmkxUUN3ME2zO{4yOjVizszN M4DlOHNCVkeHUh?=
M14 NF\VWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PhZWlEPTB;M{euNVY1OiEQvF2= NH71WVVUSU6JRWK=
786-0 NUnjfms1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN5LkK3PVQh|ryP MWXTRW5ITVJ?
MZ2-MEL NYfOeppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;QTWM2OD1|Nz60OVAyKM7:TR?= NEnBTmpUSU6JRWK=
NCI-H510A MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S5XmlEPTB;M{euPVQyOiEQvF2= NIH0No5USU6JRWK=
LAN-6 NHS1UGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TFOGlEPTB;M{euPVU5OiEQvF2= MkfNV2FPT0WU
SW620 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[zOnJKSzVyPUO4MlQ6PzRizszN MULTRW5ITVJ?
LB2241-RCC NVjkT|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPQTWM2OD1|OT64NlA2KM7:TR?= Mm\nV2FPT0WU
Detroit562 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRyLkGyOlgh|ryP MkHFV2FPT0WU
HN MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXG[ndKSzVyPUSwMlE4QDJizszN MoDkV2FPT0WU
HCT-15 NFzTSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOyeVlEUUN3ME20NE42QTB5IN88US=> NW\0Om1jW0GQR1XS
C2BBe1 M3q4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTaVpB4UUN3ME20NE46OTV5IN88US=> M4e0OXNCVkeHUh?=
A498 NVvEWXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf4dXdHUUN3ME20NU4{ODF3IN88US=> NFnDUVlUSU6JRWK=
SK-MEL-24 NGjs[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\afY5KSzVyPUSxMlQ4OjVizszN M3fyNHNCVkeHUh?=
OVCAR-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkWYc3UUN3ME20NU44PzZ5IN88US=> MWnTRW5ITVJ?
NCI-H1792 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DjXWlEPTB;NEGuPVgzOSEQvF2= MleyV2FPT0WU
KOSC-2 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfVSYV[UUN3ME20Nk4zPjl7IN88US=> NFrIZVdUSU6JRWK=
Mo-T Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXLTWM2OD12Mj64PVU5KM7:TR?= NVjNdohHW0GQR1XS
CFPAC-1 NXLSR5dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnoVlVKSzVyPUSzMlQ6PDRizszN NXfkN2hwW0GQR1XS
CAL-51 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR|LkW2NFUh|ryP NXP2RYhPW0GQR1XS
RH-18 M4jwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLkV49DUUN3ME20N{45ODVizszN M{jOV3NCVkeHUh?=
EC-GI-10 NWfDUHo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;sR2xKSzVyPUSzMlg{PDdizszN MY\TRW5ITVJ?
HSC-2 M2LhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPubm1yUUN3ME20OE4xODlizszN NWnFRlNzW0GQR1XS
ML-2 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{njVGlEPTB;NEWuNlYzOSEQvF2= NGXjU5JUSU6JRWK=
KNS-81-FD MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\rSoRWUUN3ME20OU44OzZ3IN88US=> NVvmclFvW0GQR1XS
NB6 NHHYOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fFfmlEPTB;NE[uNVEyKM7:TR?= MmmwV2FPT0WU
MCF7 NHrEUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTzTWM2OD12Nj61OVM{KM7:TR?= NGntV5lUSU6JRWK=
P30-OHK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR4LkixNVch|ryP MkTMV2FPT0WU
BPH-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHJTGR1UUN3ME20Ok46QDB3IN88US=> MUjTRW5ITVJ?
U251 M1fZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR4Lkm5OEDPxE1? NH\4OWRUSU6JRWK=
MKN1 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GyXWlEPTB;NEeuOVE{PyEQvF2= MVnTRW5ITVJ?
A431 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj2TWM2OD12Nz64N|M5KM7:TR?= MXvTRW5ITVJ?
C8166 M{\uXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHWTWM2OD12OT6yNFM6KM7:TR?= MnLjV2FPT0WU
HEL NEDqTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL6S|JKSzVyPUS5MlQxPjRizszN NYHTemNyW0GQR1XS
RMG-I MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV32ZYhNUUN3ME20PU41PDR2IN88US=> MonZV2FPT0WU
CAL-72 NGjn[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfVbGFKSzVyPUS5MlYxPzVizszN MXvTRW5ITVJ?
SW962 NFS5XIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjSTWM2OD12OT65N|MzKM7:TR?= NG\WWW9USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID